Preclinical efficacy & intermediate endpoint biomarkers IDIQ contract in support of the prevent cancer preclinical drug development program
Active Awarded Last action
- Contract number
- 75N91024D00004
- Awardee
-
The Univeristy Of Texas M.d. Anderson Cancer Center UEI S3GMKS8ELA16
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Task orders
- 2 $1,875,855 obligated
Award facts
- Opportunity
-
- Prevent IDIQ mato RFP Pre-Solicitation · 75N91023R00024 · Posted Dec 19, 2022
- Combined order value
-
- $1,875,855 Current, with exercised options
- $2,468,425 Potential, with all options
- Last date to order 55% complete
- IDV ceiling 1% used
- $149,995,000.00
- Maximum order
- $149,995,000.00
- Award type
- Multiple award
- Who can order
- Only the awarding agency
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 9 offers Negotiated Proposal / Quote
- Pricing
- Order Dependent (IDV only)
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this IDV
The National Cancer Institute awarded an indefinite-delivery contract to The University of Texas M.D. Anderson Cancer Center with a ceiling of $149,995,000 on January 25, 2024. This is a multiple-award IDIQ supporting the PREVENT Cancer Preclinical Drug Development Program and carries no set-aside designation.
The contract funds preclinical efficacy testing and intermediate endpoint biomarker evaluation of potential cancer preventive agents. Place of performance is Houston, Texas. The period of performance extends through January 24, 2029.
Under this IDIQ, MD Anderson has received two delivery orders to date: a $1,144,300 firm fixed-price order for "Time-Restricted Feeding for Pancreatic Cancer Prevention" (awarded September 20, 2024, completion December 19, 2026) and a $1,324,125 cost-sharing delivery order for "Low-Dose Erlotinib and Mesalamine for Prevention of Colitis-Associated Colorectal Cancer" (awarded September 25, 2025, completion March 24, 2027). Both orders are performed in Houston.
The originating solicitation, posted December 19, 2022 with a February 6, 2023 deadline, sought capabilities for preclinical drug efficacy assessment and biomarker development aligned with NCI's cancer prevention research agenda.
Task orders
| Task order | Ordering agency | Obligated | Awarded |
|---|---|---|---|
| Project title: low-dose erlotinib and mesalamine for prevention of colitis-associated colorectal cancer (CAC) | National Cancer Institute (NIH) | $1,324,125 | |
| Time-restricted feeding for pancreatic cancer prevention | National Cancer Institute (NIH) | $551,730 |
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 75N91024D00004?
75N91024D00004 was awarded to The Univeristy Of Texas M.d. Anderson Cancer Center by National Cancer Institute (National Institutes of Health) on January 25, 2024.
How much is contract 75N91024D00004 worth?
Orders under 75N91024D00004 have obligated $1,875,855. Their combined potential value, with all options, is $2,468,425. 75N91024D00004's own ceiling is $149,995,000. A single order can be worth up to $149,995,000.
How many orders have been placed under contract 75N91024D00004?
2 orders have been placed under 75N91024D00004, the latest on September 25, 2025.
Who can order from contract 75N91024D00004?
75N91024D00004 is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.
Is contract 75N91024D00004 part of a contract vehicle?
Yes. 75N91024D00004 is part of PRECLINICAL EFFICACY & INTERMEDIATE ENDPOINT BIOMARKERS IDIQ.
Was contract 75N91024D00004 competed?
The extent of competition for 75N91024D00004 was full and open competition. The government received 9 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV